Related Experiment Video
Updated: Jun 14, 2026

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Active Surveillance for COVID-19 Vaccine Safety Using Sequential Analysis in Korea: Population-Based Retrospective
Na-Young Jeong1, Haerin Cho2, Heehyun Won2
1Health Science Convergence Research Institute, College of Science & Industry Convergence, Ewha Womans University, Seoul, Republic of Korea.
Near real-time surveillance detected safety signals for myocarditis and anaphylaxis following COVID-19 vaccination. This approach can identify potential adverse events early for regulatory review.
Area of Science:
- Public Health
- Vaccine Safety
- Pharmacovigilance
Background:
- The introduction of new vaccines, including COVID-19 vaccines, necessitates robust near real-time active surveillance systems.
- Timely regulatory decision-making relies on efficient monitoring of vaccine safety.
- Assessing potential adverse events following immunization (AEFI) is crucial for public health.
Purpose of the Study:
- To evaluate the feasibility of using sequential monitoring for detecting potential adverse events following COVID-19 vaccination in Korea.
- To assess the timeliness of signal detection for specific adverse events compared to regulatory actions.
Main Methods:
- A population-based study utilizing linked COVID-19 registry and national health insurance claims data.
- Retrospective monthly sequential testing for prespecified outcomes (myocarditis, anaphylaxis, acute myocardial infarction) and a negative control (colonic diverticulitis).
- Poisson-based sequential probability ratio test applied to compare postvaccination incidence with background rates, accounting for multiple testing and data lags.
Main Results:
- Over 43 million monovalent and 6.3 million bivalent COVID-19 vaccine recipients were analyzed.
- Statistical safety signals for myocarditis were detected following mRNA and protein subunit vaccines.
- Signals for anaphylaxis were observed with mRNA and viral vector vaccines; no signals for acute myocardial infarction or colonic diverticulitis were found.
Conclusions:
- Near real-time sequential testing effectively identified safety signals for myocarditis and anaphylaxis post-COVID-19 vaccination.
- The detected signals were recognized by regulatory authorities, validating the approach for early detection of potential vaccine-related adverse events.
- This methodology shows promise for monitoring newly introduced vaccines and informing causality assessments promptly.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Analysis of Population Pharmacokinetic Data
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bias in Epidemiological Studies
Statistical Methods for Analyzing Epidemiological Data

